Michael LaBarre's most recent trade in Halozyme Therapeutics Inc. was a trade of 9,400 Common Stock done at an average price of $58.1 . Disclosure was reported to the exchange on Feb. 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Sale of securities on an exchange or to another person at price $ 58.09 per share. | 25 Feb 2025 | 9,400 | 176,053 (0%) | 0% | 58.1 | 546,055 | Common Stock |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Sale of securities on an exchange or to another person at price $ 58.01 per share. | 25 Feb 2025 | 9,300 | 186,153 (0%) | 0% | 58.0 | 539,465 | Common Stock |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Sale of securities on an exchange or to another person at price $ 58.25 per share. | 25 Feb 2025 | 1,597 | 173,856 (0%) | 0% | 58.3 | 93,028 | Common Stock |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Sale of securities on an exchange or to another person at price $ 58.67 per share. | 25 Feb 2025 | 700 | 185,453 (0%) | 0% | 58.7 | 41,069 | Common Stock |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Sale of securities on an exchange or to another person at price $ 58.65 per share. | 25 Feb 2025 | 600 | 175,453 (0%) | 0% | 58.6 | 35,189 | Common Stock |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Sale of securities on an exchange or to another person at price $ 58.74 per share. | 25 Feb 2025 | 100 | 173,756 (0%) | 0% | 58.7 | 5,874 | Common Stock |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 4,747 | 197,863 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 4,747 | 14,238 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.75 per share. | 23 Feb 2025 | 2,410 | 195,453 (0%) | 0% | 57.8 | 139,178 | Common Stock |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 11,902 | 11,902 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 11,230 | 11,230 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 20,891 | 196,729 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 20,891 | 0 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 8,721 | 188,008 (0%) | 0% | 58.3 | 508,347 | Common Stock |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 6,112 | 6,112 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 6,112 | 194,120 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 4,263 | 195,280 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 4,263 | 8,526 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 3,386 | 0 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 3,386 | 177,142 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 3,103 | 191,017 (0%) | 0% | 58.3 | 180,874 | Common Stock |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 2,164 | 193,116 (0%) | 0% | 58.3 | 126,140 | Common Stock |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 1,304 | 175,838 (0%) | 0% | 58.3 | 76,010 | Common Stock |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 20,342 | 20,342 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,262 | 20,891 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 4,921 | 4,921 | - | - | Performance Stock Unit | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 4,177 | 6,547 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc. | Michael LaBarre J. | SVP, CHIEF TECHNICAL OFFICER | 15 Oct 2024 | 10,000 | 173,756 (0%) | 0% | 53.3 | 532,590 | Common Stock | |
| Halozyme Therapeutics Inc. | LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | 15 Oct 2024 | 10,000 | 26,608 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 15 Oct 2024 | 10,000 | 183,756 (0%) | 0% | 20.0 | 199,800 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 15 Oct 2024 | 9,923 | 173,833 (0%) | 0% | 53.7 | 533,292 | Common Stock | |
| Halozyme Therapeutics Inc. | J. LaBarre Michael | SVP, CHIEF TECHNICAL OFFICER | 15 Oct 2024 | 5,509 | 179,265 (0%) | 0% | 16.7 | 91,725 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 15 Oct 2024 | 5,509 | 6,352 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | LaBarre J. Michael | SVP, CHIEF TECHNICAL OFFICER | 15 Oct 2024 | 4,491 | 183,756 (0%) | 0% | 20.0 | 89,730 | Common Stock | |
| Halozyme Therapeutics Inc. | LaBarre J. Michael | SVP, CHIEF TECHNICAL OFFICER | 15 Oct 2024 | 4,491 | 36,608 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 15 Oct 2024 | 77 | 173,756 (0%) | 0% | 54.2 | 4,177 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 17 Sep 2024 | 10,000 | 21,861 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 17 Sep 2024 | 10,000 | 183,756 (0%) | 0% | 16.7 | 166,500 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 17 Sep 2024 | 10,000 | 173,756 (0%) | 0% | 62.9 | 628,780 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 17 Sep 2024 | 10,000 | 183,756 (0%) | 0% | 16.7 | 166,500 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 17 Sep 2024 | 10,000 | 11,861 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 17 Sep 2024 | 7,963 | 175,793 (0%) | 0% | 61.9 | 492,838 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 17 Sep 2024 | 2,037 | 173,756 (0%) | 0% | 62.6 | 127,477 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 27 Aug 2024 | 5,580 | 0 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 27 Aug 2024 | 5,580 | 173,756 (0%) | 0% | 18.4 | 102,728 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 20 Aug 2024 | 10,000 | 31,861 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 20 Aug 2024 | 10,000 | 168,176 (0%) | 0% | 61.1 | 610,550 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 20 Aug 2024 | 10,000 | 178,176 (0%) | 0% | 16.7 | 166,500 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 20 Aug 2024 | 10,000 | 178,176 (0%) | 0% | 16.7 | 166,500 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 20 Aug 2024 | 10,000 | 41,861 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 20 Aug 2024 | 9,900 | 168,276 (0%) | 0% | 61.7 | 611,236 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 20 Aug 2024 | 100 | 168,176 (0%) | 0% | 62.3 | 6,234 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 23 Jul 2024 | 10,000 | 178,176 (0%) | 0% | 8.1 | 81,100 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 23 Jul 2024 | 10,000 | 1,715 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 23 Jul 2024 | 10,000 | 168,176 (0%) | 0% | 55.1 | 551,150 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 23 Jul 2024 | 8,285 | 51,861 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 23 Jul 2024 | 8,285 | 178,176 (0%) | 0% | 16.6 | 137,945 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 23 Jul 2024 | 5,291 | 168,176 (0%) | 0% | 55.3 | 292,407 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 23 Jul 2024 | 4,709 | 173,467 (0%) | 0% | 54.5 | 256,466 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 23 Jul 2024 | 1,715 | 0 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 23 Jul 2024 | 1,715 | 169,891 (0%) | 0% | 8.1 | 13,909 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 18 Jun 2024 | 10,000 | 11,715 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 18 Jun 2024 | 10,000 | 168,176 (0%) | 0% | 49.4 | 494,260 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 18 Jun 2024 | 10,000 | 178,176 (0%) | 0% | 8.1 | 81,100 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 21 May 2024 | 10,000 | 178,176 (0%) | 0% | 8.1 | 81,100 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 21 May 2024 | 10,000 | 21,715 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 21 May 2024 | 10,000 | 31,715 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 21 May 2024 | 10,000 | 168,176 (0%) | 0% | 45.4 | 453,840 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 21 May 2024 | 10,000 | 178,176 (0%) | 0% | 8.1 | 81,100 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 21 May 2024 | 10,000 | 168,176 (0%) | 0% | 45.2 | 451,640 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 16 Apr 2024 | 10,000 | 178,176 (0%) | 0% | 8.1 | 81,100 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 16 Apr 2024 | 10,000 | 41,715 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 16 Apr 2024 | 10,000 | 51,715 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 16 Apr 2024 | 10,000 | 168,176 (0%) | 0% | 38.5 | 384,890 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 16 Apr 2024 | 10,000 | 178,176 (0%) | 0% | 8.1 | 81,100 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 16 Apr 2024 | 10,000 | 168,176 (0%) | 0% | 38.4 | 383,500 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 26 Mar 2024 | 8,436 | 0 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 26 Mar 2024 | 8,436 | 164,994 (0%) | 0% | 12.1 | 101,823 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 26 Mar 2024 | 2,890 | 168,176 (0%) | 0% | 8.1 | 23,438 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 26 Mar 2024 | 2,890 | 61,715 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 26 Mar 2024 | 292 | 0 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 26 Mar 2024 | 292 | 165,286 (0%) | 0% | 16.8 | 4,900 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 12 Mar 2024 | 10,000 | 166,558 (0%) | 0% | 12.1 | 120,700 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 12 Mar 2024 | 10,000 | 14,885 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 12 Mar 2024 | 10,000 | 156,558 (0%) | 0% | 42.3 | 422,730 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 12 Mar 2024 | 10,000 | 156,558 (0%) | 0% | 41.6 | 416,370 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 12 Mar 2024 | 6,449 | 8,436 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 12 Mar 2024 | 6,449 | 163,007 (0%) | 0% | 12.1 | 77,839 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 12 Mar 2024 | 3,551 | 166,558 (0%) | 0% | 8.1 | 28,799 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 12 Mar 2024 | 3,551 | 64,605 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 27 Feb 2024 | 10,000 | 159,087 (0%) | 0% | 39.9 | 399,460 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 27 Feb 2024 | 7,471 | 68,156 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | LaBarre Michael | SVP, CHIEF TECHNICAL OFFICER | 27 Feb 2024 | 7,471 | 156,558 (0%) | 0% | 39.5 | 295,418 | Common Stock | |
| Halozyme Therapeutics Inc. | LaBarre Michael | SVP, CHIEF TECHNICAL OFFICER | 27 Feb 2024 | 7,471 | 164,029 (0%) | 0% | 8.1 | 60,590 | Common Stock | |
| Halozyme Therapeutics Inc. | LaBarre Michael | SVP, CHIEF TECHNICAL OFFICER | 27 Feb 2024 | 2,529 | 156,558 (0%) | 0% | 39.6 | 100,045 | Common Stock | |
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 23 Feb 2024 | 19,674 | 19,674 | - | - | Option to Purchase Common Stock | ||
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 23 Feb 2024 | 18,985 | 18,985 | - | - | Restricted Stock Units | ||
| Halozyme Therapeutics Inc. | LaBarre Michael | SVP, CHIEF TECHNICAL OFFICER | 16 Feb 2024 | 6,112 | 12,224 | - | - | Restricted Stock Units | ||
| Halozyme Therapeutics Inc. | LaBarre Michael | SVP, CHIEF TECHNICAL OFFICER | 16 Feb 2024 | 6,112 | 170,080 (0%) | 0% | 0 | Common Stock | ||
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 16 Feb 2024 | 4,264 | 171,247 (0%) | 0% | 0 | Common Stock | ||
| Halozyme Therapeutics Inc. | Michael LaBarre | SVP, CHIEF TECHNICAL OFFICER | 16 Feb 2024 | 4,264 | 12,789 | - | - | Restricted Stock Units |